All In MedTech

Device Trial Radar · NCT03579875

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

MT2017-17:T Cell Receptor Alpha/Beta T Cell Depleted Hematopoietic Cell Transplantation in Patients With Inherited Bone Marrow Failure (BMF) Disorders

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Nov 13, 2018

Primary completion

Jan 1, 2027

Study completion Jan 5, 2029

Sponsor

Lead sponsor
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 9, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.

Conditions

  • Fanconi Anemia
  • Severe Aplastic Anemia
  • Myelodysplastic Syndromes
  • T Cell Receptor Alpha/Beta Depletion
  • Telomere Biology Disorder
  • Bone Marrow Failure
  • Dyskeratosis Congenita
  • Telomere Biology Disorders

Interventions

  • Total Body Irradiation (TBI) (Plan 1)Drug

    300 cGy with thymic shielding on day -6

  • Cyclophosphamide (CY) (Plan 1)Drug

    10 mg/kg IV daily on days -5, -4, -3, and -2

  • Fludarabine (FLU)Drug

    35 mg/m2 IV daily on days -5, -4, -3, and -2

  • Methylprednisolone (MP)Drug

    1 mg/kg IV q12h on days -5, -4, -3, -2, and -1

  • Donor mobilized PBSC infusionDevice

    T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0

  • G-CSFDrug

    Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days or single day ANC \>3000 Arm 1 and Arm 3)

  • Cyclophosphamide (CY) (Plan 2)Drug

    5 mg/kg IV daily on days -5, -4, -3, and -2

  • RituximabDrug

    200 mg/m2 IV once on day -1

  • BusulfanDrug

    Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.

  • AlemtuzumabDrug

    Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)

  • MelphalanDrug

    If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.

  • RituximabDrug

    Rituximab will be given once on treatment plans 1-3 on day -1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Grade II-IV acute graft versus host disease (GVHD)Time frame: Day 100

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Masonic Cancer Center at University of Minnesota

    Minneapolis, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.